methyl (S)-3-oxo-1-phenylbutylcarbamate

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl (S)-3-oxo-1-phenylbutylcarbamate
• 英文别名: methyl N-[(1S)-3-oxo-1-phenylbutyl]carbamate
• 化学式: C₁₂H₁₅NO₃
• 分子量: 221.256
• InChiKey: QRKCOWNGICFRML-NSHDSACASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  55.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  Methyl [(benzenesulfonyl)(phenyl)methyl]carbamate 、 乙酰乙酸烯丙酯 在 bis(η3-allyl-μ-chloropalladium(II)) sodium carbonate 、 sodium chloride 、 辛可宁 、 (+/-)-2,3-O-isopropylidene-2,3-dihydroxy-1,4-bis(diphenylphosphino)butane 、 乙酰乙酸甲酯 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 51.0h， 生成 (R)-(3-oxo-1-phenyl-butyl)-carbamic acid methyl ester 、 methyl (S)-3-oxo-1-phenylbutylcarbamate
  参考文献：
  名称：

  金鸡纳生物碱催化二羰基化合物与α-酰胺基砜的不对称曼尼希反应及手性二氢嘧啶酮的合成

  摘要：

  描述了二羰基化合物与α-酰胺基砜作为酰基亚胺前体的高度对映选择性金鸡纳生物碱催化的曼尼希反应。该反应需要10 mol％的金鸡纳生物碱催化剂和Na 2 CO 3水溶液，该催化剂可作为一般的碱在现场生成酰基亚胺。保持游离生物碱催化剂的浓度。以高收率和高对映选择性以及从1∶1至＞ 95∶5的非对映选择性获得反应产物。辛可宁催化的反应提供了高度实用的结构单元的实际途径，该结构单元已用于手性二氢嘧啶酮的合成，手性二氢嘧啶酮是一类具有多种生物活性的化合物。二氢嘧啶酮修饰包括使用H-Cube流动氢化器和Rh（II）介导的1,3-偶极环加成反应对烯酰胺部分进行高度非对映选择性氢化，以提供高度官能化的复杂杂环。

  DOI：

  10.1021/jo701777g

文献信息

• HEPATITIS C VIRUS INHIBITORS
  申请人：Qiu Yao-Ling

  公开号：US20110064695A1

  公开（公告）日：2011-03-17

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention relates to novel antiviral compounds represented herein above, pharmaceutical compositions comprising such compounds, and methods for the treatment or prophylaxis of viral (particularly HCV) infection in a subject in need of such therapy with said compounds.

  本发明公开了化合物的结构式（I），或其药学上可接受的盐、酯或前药： 这些化合物抑制RNA含病毒，特别是丙型肝炎病毒（HCV）。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，并且也可用作抗病毒剂。本发明还涉及包含上述化合物的药物组合物，用于治疗患有HCV感染的受试者。该发明还涉及通过给予包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。本发明涉及上述新型抗病毒化合物，包括含有这些化合物的药物组合物，以及用于治疗或预防受试者需要此类治疗的病毒（特别是HCV）感染的方法。
• ANTIVIRAL AGENTS
  申请人：Or Yat Sun

  公开号：US20110218175A1

  公开（公告）日：2011-09-08

  The present invention relates to antiviral compounds of formula (I), compositions containing these compounds, processes for their preparation, intermediates in their synthesis, and their use as therapeutics for prevention of organ transplantation rejection, the treatment of immune disorders and inflammation, and treatment of viral (particularly hepatitis C viral) infection.

  本发明涉及公式（I）的抗病毒化合物，含有这些化合物的组合物，其制备方法，合成中间体，以及它们作为用于预防器官移植排斥、治疗免疫紊乱和炎症，以及治疗病毒（尤其是丙型肝炎病毒）感染的治疗药物的用途。
• Enzymatic Synthesis of Enantiomerically Pure β-Amino Ketones, β-Amino Esters, and β-Amino Alcohols with Baeyer-Villiger Monooxygenases
  作者：Jessica Rehdorf、Marko D. Mihovilovic、Marco W. Fraaije、Uwe T. Bornscheuer

  DOI：10.1002/chem.201001480

  日期：2010.8.16

  The enzymatic kinetic resolution of a broad set of β‐amino ketones was investigated by using a collection of 16 Baeyer–Villiger monooxygenases from different bacterial origins, which display various substrate specificities. Within this platform of enzymes excellent enantioselectivities (E>200) were found towards aliphatic and aromatic 4‐amino‐2‐ketones, and some enzymes even showed opposite enantioselectivity

  通过收集来自不同细菌来源的16种Baeyer-Villiger单加氧酶的集合，研究了广泛的β-氨基酮的酶促动力学拆分，这些酶具有不同的底物特异性。在这种酶的平台上，发现对脂肪族和芳香族的4-氨基-2-酮具有极好的对映选择性（E > 200），有些酶甚至表现出相反的对映选择性。中间体β-氨基烷基乙酸酯经过自动水解，生成光学纯的β-氨基醇，它们是合成天然药物和医药行业高度关注的生物活性化合物的关键中间体。此外，在某些情况下，形成了异常的酯。
• LINKED DIBENZIMIDAZOLE DERIVATIVES
  申请人：Qiu Yao-Ling

  公开号：US20100221215A1

  公开（公告）日：2010-09-02

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
• LINKED DIIMIDAZOLE ANTIVIRALS
  申请人：Or Yat Sun

  公开号：US20100226882A1

  公开（公告）日：2010-09-09

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.